Early diagnosis is central to improving outcomes for patients with cancer. For cancers without specific risk factors, or with no screening programs are difficult to diagnose and patients often present with non-specific symptoms. Unfortunately this means that these patients are often diagnosed late on in the development of the disease and treatment options are reduced.
Using Fourier transform infrared (FTIR) spectroscopy, we are aiming to create a blood test that would help identify patients who have a high likelihood of cancer. To do so we are collecting blood samples from: i) participants for whom the assessing clinician has identified a clinical need to undergo a diagnostic investigation to exclude a new brain, chest, abdominal or pelvic abnormality, where the differential diagnosis includes cancer, or ii) participants with a recent new cancer diagnosis, before surgery, chemotherapy or radiotherapy. We will use the data from anlaysed samples, and machine learning, to train an algorithm to ascertain whether a new cancer diagnosis can be accurately predicted at the time of presentation with non-specific symptoms. This would permit prioritisation for diagnostic imaging, support clinical decision making and hopefully earlier diagnosis.
Consultant Neurosurgeon
Senior Research Nurse
Research Project Manager
Senior Research Nurse
Senior Research Nurse
Stroke Lead Research Nurse
AMU Senior Research Nurse
Senior Research Nurse
Senior Research Nurse - Renal/Acute Medicine
Senior Research Nurse
Clinical Trial Assistant
Senior Research Nurse - Stroke/Neurosurgery
Lead Research Nurse
Senior Research Nurse
Senior Research Nurse
Senior Research Nurse - Stroke/Neurosurgery
Senior Research Nurse
Lead Research Nurse
Senior Stroke Research Nurse
Research Administrator
Early diagnosis is central to improving outcomes for patients with cancer. For cancers without specific risk factors, or with no screening programs are difficult to diagnose and patients often present with non-specific symptoms. Unfortunately this means that these patients are often diagnosed late on in the development of the disease and treatment options are reduced.
DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions